While further acquisitions are on hold for the immediate future while the current expansion is “digested”, Dikansky said the company’s aggressive takeover policy remained unchanged and that further activity was likely to occur in the medium to long term.
He said the terms of the Natraceutical deal was not altered by the economic recession that had not affected the nutraceutical industry as severely as it had some other industries.
The new entity has annual turnover in the vicinity of €200m – about twice Naturex’s 2008 turnover of €93.2m.